The Mycelium Authorization That Changes the Protein Innovation Equation · Rhizomucor pusillus, protected novel-food evidence and the industrial economics of fungal biomass in 2026
Year: 2026
Type: article
Abstract: The European Union's July 2026 authorisation of Rhizomucor pusillus mycelium marks more than another entry on the novel-food list. It establishes a defined, strain-specific and process-specific route to market for a fermented fungal biomass containing substantial protein and dietary fibre, while reserving the initial commercial benefit to an applicant whose protected evidence supported the safety assessment. This article examines the resulting tension between biotechnology, nutrition, process engineering and regulatory exclusivity. It evaluates what the EFSA opinion actually establishes, what the authorisation permits, why crude protein is not synonymous with nutritional performance, and how fermentation economics can be undermined by downstream processing, variability and market access. The comparison extends to Great Britain and Australia–New Zealand, where separate assessments remain relevant. A proposed research programme focuses on the interaction of fungal cell-wall architecture, digestibility, processing stability and formulation behaviour. The central argument is that the next competitive advantage will depend less on producing biomass than on demonstrating reproducible functionality, defensible nutrition and legally accessible commercialisation.
Author: López, José M.
Language: English
Subfield: Food Science
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7233545225
FWCI:
Cites:
Cited by:
Related to:
